RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Aiming, Yes, and a bigger concern is Org-24448. I'll have to re-listen to the presentation, but while Dr. Stoll seemed to suggest that he didn't think this cellular problem has been noted in Org-24448, I'm not going to assume that yet. If they do tox trials on Org-24448 specifically looking for the same type cellular changes, who knows what they might turn up at really high doses. Up to recently, Ampakine dose levels in animal tox trials have been limited by nausea/emesis problems. Cortex was able to boost the levels considerably in doing the recent repeat studies. Who knows what doses they originally used with Org-24448 (probably lower than what can now be done). Dr. Stoll said the histologists hadn't even seen cellular changes of this type previously, so they're not familiar with what the hell might be causing them. The technology is brand new so there is no framework by which to evaluate the cellular phenomenon.

What Cortex needs to do now is do massive tox work-ups on both CX-701 and the other backup, and see if the cellular changes happen again. If they don't, we have a huge setback but the low impact platform has a future. If the do, the entire low impact platform could be history.